Sodium‐glucose cotransporter 2 inhibitor luseogliflozin improves glycaemic control, assessed by continuous glucose monitoring, even on a low‐carbohydrate diet

Por Nishimura, R., Omiya, H., Sugio, K., Ubukata, M., Sakai, S., Samukawa, Y.
Publicado no Diabetes Obes Metab (2016)

Carcinogenicity in mice and rats of heterocyclic amines in cooked foods.

Por Ohgaki, H, Hasegawa, H, Kato, T, Suenaga, M, Ubukata, M, Sato, S, Takayama, S, Sugimura, T
Publicado em 1986

Effects of luseogliflozin, a sodium–glucose co‐transporter 2 inhibitor, on 24‐h glucose variability assessed by continuous glucose monitoring in Japanese patients with type 2 diabe...

Por Nishimura, R., Osonoi, T., Kanada, S., Jinnouchi, H., Sugio, K., Omiya, H., Ubukata, M., Sakai, S., Samukawa, Y.
Publicado no Diabetes Obes Metab (2015)